School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia.
Monash Addiction Research Centre, Eastern Health Clinical School, Monash University and Turning Point, Melbourne, Australia.
Drug Alcohol Rev. 2024 Jul;43(5):1280-1293. doi: 10.1111/dar.13847. Epub 2024 Apr 17.
Strong patient interest in the use of medicinal cannabis to treat various clinical indications has sparked global legislative changes. Practitioners are vital in implementing regulatory changes and facilitating patient access to medicinal cannabis, however, little is currently known about the factors influencing practitioners' uptake. Recent rapid increases in practitioner applications to prescribe medicinal cannabis in Australia provides a unique backdrop to examine the current factors influencing prescribing behaviours. This qualitative study examined Australian practitioners' perspectives on prescribing medicinal cannabis to provide a comprehensive exploration of the potential factors influencing uptake in clinical practice.
Seventeen semi-structured interviews were conducted with Australian health-care practitioners. Transcripts were analysed using the Framework approach to thematic analysis and cross-mapped to appropriate domains of the Theoretical Domains Framework.
We identified four themes related to the barriers and facilitators to prescribing medicinal cannabis: (i) clinical capabilities needed to prescribe; (ii) prescribing an unapproved therapeutic good; (iii) negative attitudes towards prescribers in the medical community; and (iv) divergent beliefs about clinical utility.
Practitioners face multiple pervasive barriers to prescribing medicinal cannabis. Beliefs about clinical utility appear to be highly influential in shaping prescribing behaviours. Moreover, our findings suggest that a medicinal cannabis 'specialisation' has emerged within the Australian medical community. Findings demonstrate that a range of complex and multifaceted factors influence practitioners' medicinal cannabis prescribing behaviours. We highlight several considerations for policy and practice to support safe and appropriate patient access to medicinal cannabis in this emerging area of clinical practice.
患者对药用大麻治疗各种临床病症的强烈兴趣引发了全球立法变革。从业者在实施监管变革和促进患者获得药用大麻方面至关重要,但目前对于影响从业者接受度的因素知之甚少。最近,澳大利亚从业者申请开具药用大麻的数量迅速增加,为研究目前影响处方行为的因素提供了独特的背景。本定性研究考察了澳大利亚从业者开具药用大麻处方的观点,全面探讨了影响临床实践中接受度的潜在因素。
对 17 名澳大利亚医疗保健从业者进行了半结构化访谈。使用框架方法对主题分析进行了转录,并与理论领域框架的适当领域进行了交叉映射。
我们确定了与开具药用大麻的障碍和促进因素相关的四个主题:(i)开具处方所需的临床能力;(ii)开具未经批准的治疗性药物;(iii)医疗界对开处方者的负面态度;以及(iv)对临床效用的不同信念。
从业者在开具药用大麻处方方面面临多种普遍障碍。对临床效用的信念似乎对处方行为具有高度影响力。此外,我们的研究结果表明,在澳大利亚医疗界出现了一种药用大麻“专业化”。研究结果表明,一系列复杂和多方面的因素影响着从业者的药用大麻处方行为。我们强调了一些政策和实践方面的考虑因素,以支持在这一新兴临床实践领域中安全和适当的患者获得药用大麻。